LTFOX | Affiliated Fund Class F3 | Lord Abbett

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

 

Affiliated Fund

Track this Fund
Add to Hypo Tool

Summary

Summary

What is the Affiliated Fund?

The Fund seeks to deliver long-term growth of capital and current income by investing primarily in dividend-paying stocks of large U.S. companies.

DIVIDEND PAYERS

True to its mandate, the Affiliated Fund is focused on companies that pay dividends.

VALUE FOCUSED

We believe a professionally-managed approach can identify companies with sustainable dividend policies whose stocks are attractively valued. 

GROWTH & INCOME

A portfolio of undervalued dividend-paying stocks may provide investors with long-term growth of capital and current income. 

Fund Basicsas of 05/31/2022

Total Net Assets
$5.90 B
Inception Date
04/05/2017
Dividend Frequency
Quarterly
Fund Expense Ratio
0.38%
Number of Holdings
62

Yield

12-Month Dividend Yield 1 as of 06/24/2022  

w/o sales charge 2.07%

30-Day Standardized Yield 2 as of 05/31/2022  

1.81%

Fund Expense Ratio :

0.38%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -9.21% -0.93% 10.21% 8.10% 11.50% -
Lipper Category Avg. Equity Income Funds -4.52% 2.85% 12.81% 9.66% 11.17% -
Russell 1000® Value Index -4.52% 0.93% 12.75% 9.50% 12.06% -

Fund Expense Ratio :

0.38%

Fund Expense Ratio :

0.38%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -4.29% 11.77% 11.03% 9.48% 11.08% -
Lipper Category Avg. Equity Income Funds -1.34% 12.94% 13.07% 10.69% 10.88% -
Russell 1000® Value Index -0.74% 11.67% 13.02% 10.29% 11.70% -

Fund Expense Ratio :

0.38%

RELATED CONTENT

Investing in Stocks: The Case for a Broader Global Focus
August 30, 2021

An allocation to non-U.S. equities could provide an effective complement to a U.S.-focused stock portfolio. Here’s why

TEN LARGEST HOLDINGS as of 05/31/2022View Portfolio

Holding Assets
UnitedHealth Group Inc 4.3%
NextEra Energy Inc 3.6%
Pfizer Inc 3.4%
Morgan Stanley 3.3%
Marathon Petroleum Corp 3.1%
AbbVie Inc 2.9%
Chevron Corp 2.9%
Shell PLC 2.9%
Allstate Corp/The 2.8%
Northrop Grumman Corp 2.8%
% of Total Assets 32.1%

INVESTMENT TEAM

Darnell Azeez
Darnell Azeez, CFA

Managing Director, Portfolio Manager

20 Years of Industry Experience

Marc O. Pavese
Marc O. Pavese, Ph.D.

Partner & Director of Quantitative Research

22 Years of Industry Experience

Ryan C. Howard
Ryan C. Howard, CFA

Portfolio Manager

19 Years of Industry Experience

Servesh Tiwari
Servesh Tiwari, CFA

Portfolio Manager

16 Years of Industry Experience

Supported By 35 Investment Professionals with 19 Years Avg. Industry Experience

Your Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

12-Month Dividend Yield 1 as of 06/24/2022  

w/o sales charge 2.07%

30-Day Standardized Yield 2 as of 05/31/2022  

  Subsidized3 Un-Subsidized4
w/o sales charge 1.81% 1.81%

Fund Expense Ratio :

0.38%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -9.21% -0.93% 10.21% 8.10% 11.50% -
Lipper Category Avg. Equity Income Funds -4.52% 2.85% 12.81% 9.66% 11.17% -
Russell 1000® Value Index -4.52% 0.93% 12.75% 9.50% 12.06% -

Fund Expense Ratio :

0.38%

Fund Expense Ratio :

0.38%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception
w/o sales charge -4.29% 11.77% 11.03% 9.48% 11.08% -
Lipper Category Avg. Equity Income Funds -1.34% 12.94% 13.07% 10.69% 10.88% -
Russell 1000® Value Index -0.74% 11.67% 13.02% 10.29% 11.70% -

Fund Expense Ratio :

0.38%

Year Fund Returns Russell 1000® Value Index
2021 27.12% 25.16%
2020 -0.95% 2.80%
2019 25.69% 26.54%
2018 -7.09% -8.27%
2017 16.40% 13.66%
2016 17.83% 17.34%
2015 -3.83% -3.83%
2014 12.34% 13.45%
2013 32.80% 32.53%
2012 16.36% 17.51%
2011 -7.47% -
2010 14.87% -
2009 19.94% -
2008 -36.87% -
2007 4.13% -
2006 - -
Year Q1 Q2 Q3 Q4 Yearly Returns
2022 -4.29% - - - -14.57%
2021 8.86% 5.71% -0.03% 10.49% 27.12%
2020 -27.86% 15.61% 5.43% 12.64% -0.95%
2019 10.68% 3.85% 2.56% 6.62% 25.69%
2018 -2.30% 0.57% 6.63% -11.32% -7.09%
2017 4.15% 2.12% 3.10% 6.16% 16.40%
2016 2.59% 3.28% 3.83% 7.10% 17.83%
2015 0.50% -1.14% -7.49% 4.62% -3.83%
2014 2.30% 4.13% -0.02% 5.49% 12.34%
2013 11.06% 3.95% 4.59% 9.98% 32.80%
2012 12.69% -4.57% 6.69% 1.41% 16.36%
2011 5.68% -2.57% -20.73% 13.37% -7.47%
2010 6.89% -14.30% 10.44% 13.55% 14.87%
2009 -16.35% 18.86% 16.46% 3.58% 19.94%
2008 -9.60% -5.95% -6.59% -20.51% -36.87%
2007 0.43% 5.27% 1.95% -3.39% 4.13%
2006 - - - 5.52% -

NAV HISTORICAL PRICES

Date Net Asset Value

Portfolio

Portfolio

Portfolio Positioningas of 03/31/2022

  • As of March 31, 2022, the Fund’s largest overweight position relative to its benchmark, the Russell 1000® Value Index, is in AbbVie Inc., a research-based biopharmaceutical company. We believe the company has a diverse portfolio focused on therapeutic areas of immunology, hematologic oncology, aesthetics, neuroscience, eye care and women’s health. While there is an expectation of deceleration in its top grossing Humira franchise, we expect surging growth in several newer immunology assets including Rinvoq and Skyrizi, as well as continued strength in the aesthetics portfolio obtained in the recent acquisition of Allergan plc, which will enable continued top and bottom-line growth.
  • The Fund is overweight relative to its benchmark in NextEra Energy, an electric power and energy infrastructure company. We continue to view NextEra as a standout performer in the electric utility industry as they grow both their regulated and non-regulated businesses. We believe they are a top renewable energy play and will benefit as the demand for renewables continues to rise.
  • The Fund is also overweight relative to its benchmark in Morgan Stanley, a global provider of investment banking, capital market, management, and other financial services to corporations, institutions, and individuals. We believe the company is well-positioned for the secular trends in wealth management given its unique vertical integration of the corporate stock plan, online brokerage, and asset management businesses, and is also well-positioned for both rising rates and a rebound in capital markets activity. Further, we feel the company is in a better position to optimize its capital base, which should lead to enhanced profitability and buttress capital returns to shareholders over time.

PORTFOLIO DETAILS as of 05/31/2022

Total Net Assets
$5.90 B
Number of Holdings
62
Weighted Average Market Cap.
219.2 B
P/B Ratio
3.3x
P/E Ratio
15.2x

Contributors & Detractors as of  03/31/2022

Contributors

Holding Contribution
Chevron Corp 0.8%
Marathon Petroleum Corp. 0.8%
AbbVie, Inc. 0.7%
Cheniere Energy Inc 0.4%
Northrop Grumman Corp 0.3%

Detractors

Holding Contribution
Home Depot Inc/The -0.5%
Danaher Corp Del -0.5%
First Citizens BancShares, Inc -0.4%
Lowe's Cos Inc -0.4%
Kkr & Co Inc -0.3%

Attribution Analysis 

Affiliated Fund Benchmark Variance
Sector Avg. Weight Base Return Avg. Weight Base Return Stock Selection Group Weight Total

Dividends & Cap Gains

Dividends & Cap Gains

Dividend Payments

For
YTD Dividends Paidas of 06/24/2022
$0.077
Dividend Frequency
Quarterly
Record Date Ex-Dividend Date Reinvest & Payable Date Dividend Reinvest Price
03/29/2022 03/30/2022 03/30/2022 $0.07780 $18.17

Upcoming Dividend Payment Dates

This section lists all anticipated income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date Reinvest & Payable Date
06/28/2022 06/29/2022 06/29/2022
09/28/2022 09/29/2022 09/29/2022
12/27/2022 12/28/2022 12/28/2022

Capital Gains Distributions

For
Record Date Reinvest & Payable Date Long-term Short-term * Total Reinvest Price
11/22/2021 11/23/2021 $0.4534 - $0.4534 $18.54

Upcoming Capital Gain Distribution

This section lists all anticipated income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date
11/21/2022 11/22/2022

Fees & Expenses

Fees & Expenses

Fund Documents

Fund Documents

Download fund documents & literature, create email subscriptions, and place direct mail order

0Documents selected
Order
n/a
Portfolio Holdings 1Q
Publish Date:11/03/2015
n/a
Portfolio Holdings 3Q
Publish Date:11/03/2015
Summary Prospectus
Publish Date:11/03/2015
n/a
Statutory Prospectus
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Report
Publish Date:11/03/2015
Semi-Annual Report
Publish Date:11/03/2015
Fact Sheet
Publish Date:11/03/2015
Commentary
Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

The Russell 1000® Value Index measures the performance of those Russell 1000 companies with lower price-to-book ratios and lower forecasted growth values.

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field